Only subtle microglial changes are detected during disease onset and progression in rNLS8 SC. Our previous studies characterized the disease course in rNLS8 mice following induction of Though motor neurons selectively degenerate in amyotrophic lateral sclerosis, other cell types are likely involved in this disease. We recently generated rNLS8 mice in which human TDP-43 (hTDP-43) pathology could be reversibly induced in neurons and expected that microglia would contribute to neurodegeneration. However, only subtle microglial changes were detected during disease in the spinal cord, despite progressive motor neuron loss; microglia still reacted to inflammatory triggers in these mice. Notably, after hTDP-43 expression was suppressed, microglia dramatically proliferated and changed their morphology and gene expression profiles. These abundant, reactive microglia selectively cleared neuronal hTDP-43. Finally, when microgliosis was blocked during the early recovery phase using PLX3397, a CSF1R and c-kit inhibitor, rNLS8 mice failed to regain full motor function, revealing an important neuroprotective role for microglia. Therefore, reactive microglia exert neuroprotective functions in this amyotrophic lateral sclerosis model, and definition of the underlying mechanism could point toward novel therapeutic strategies. NATuRe NeuRoSCieNCe | VOL 21 | MARCH 2018 | 329-340 | www.nature.com/natureneuroscience 329
R eactive microglia have been hypothesized to increase the severity of several neurodegenerative disorders 1 , but recently there is a growing appreciation that the nature of the microglial reaction to CNS pathology is not uniform but is contingent on the timing and diversity of microglial subtypes involved. Further, emerging data reveal fundamental roles for microglia in maintaining homeostasis 2 , including controlling the formation of synapses 3 , refining neuronal circuits, eliminating redundant synapses 4 and facilitating neurotrophin-mediated healing responses to injury 5 . Currently, both microglial-mediated neurotoxicity and neuroprotection in disease are active areas of research.
Microglia have been specifically implicated in amyotrophic lateral sclerosis (ALS). For example, CD68 + microglia were found to be dispersed in degenerating white matter of postmortem sporadic ALS (sALS) spinal cord (SC), though much less extensively in the ventral horns 6 . Clinically, positron emission tomography (PET) radiotracers show increased glial activation in motor and extramotor cerebral regions in small groups of ALS patients during disease progression [7] [8] [9] . Additionally, several studies have measured alterations in cytokines in cerebrospinal fluid from ALS patients during disease 10, 11 . However, studies that examined gene-expression changes in SC samples from sALS patients did not find changes in microglia-specific genes or pathways 12, 13 .
The majority of research on the role of microglia in ALS comes from studies in the most commonly used model of familial ALS, mSOD1 mice, in which mSOD1 in microglia was shown to contribute to the disease progression [14] [15] [16] .When microglial proliferation or function was blocked, there was an amelioration of the disease in mSOD1 mice 17, 18 . Given that SOD1 is a ubiquitously expressed protein that is normally secreted by microglia under physiological conditions and that has been shown to be neuroprotective 19 , and given that most ALS patients (~97%) do not have mutations in this gene, it is important to examine neuroinflammation in patients without SOD1 mutations, as well as in a mouse model that may be more relevant to the majority of ALS cases.
As > 90% of ALS patients have an accumulation of cytoplasmic TDP-43 aggregates in postmortem SC 20 and as aberrant forms of TDP-43 have been implicated in motor neuron (MN) death 21, 22 , we propose that investigating non-cell-autonomous changes in the SC in response to pathological TDP-43 may be more disease-relevant. Some studies have shown that TDP-43 is associated with increased levels of neuroinflammatory markers [23] [24] [25] , but it has been difficult to assess the direct effects of TDP-43 aggregates on microglia activation in vivo. We therefore used our new inducible mouse model of ALS, rNLS8 mice 26 , to examine the relationship between TDP-43, disease onset and progression, and neuroinflammation. rNLS8 mice express hTDP43∆NLS in neurons in a doxycycline (DOX)-dependent manner, such that hTDP43∆NLS expression is suppressed in the presence of DOX 26 , allowing us to induce the formation of TDP-43 aggregates and measure microglial responses. Moreover, we have previously shown that when we halt disease by suppressing hTDP43ΔNLS, pathological TDP-43 is cleared, MN loss ceases and the surviving MNs innervate vacated neuromuscular junctions 26, 27 . Thus, we can also use this model to examine the relationship between these regenerative events and changes in microglia.
hTDP43ΔNLS in the primary affected cells, neurons 26 (Fig. 1a ). Next, we characterized changes in microglia from rNLS8 mice before and during disease. We confirmed that hTDP-43 is not expressed in microglia in rNLS8 mice upon DOX removal ( Supplementary Fig. 1 ), such that any changes we observe reflect a response to chronic neuronal hTDP43ΔNLS expression rather than a direct impact on microglia themselves. Unexpectedly, we did not find substantial changes in microglia density in the SC (P = 0.004) and no changes in microglial morphology during the disease course (key timepoints shown in Fig. 1b-g) , even after 8 weeks of expression, by which time substantial MN death has occurred and the remaining MNs have cytoplasmic accumulations of hTDP-43 and nuclear clearance of endogenous TDP-43 (Fig. 1d,g and Supplementary Fig. 1 ). Quantification of IBA-1 + cells per mm 2 or percent area occupied by CD68 further confirmed that there was only a ~10% increase in the number of microglia at lumbar SCs of rNLS8 mice at 6 weeks off DOX compared to rNLS8 mice on DOX and no change in CD68 at 2, 4 or 6 weeks off DOX ( Fig. 1h-i) .
To test the ability of these glia to respond to canonical inflammatory stimuli, we either performed a unilateral sciatic nerve crush or injected lipopolysaccharide (intraperitoneally, i.p.) in rNLS8 mice at 2 weeks off DOX, when neurons exhibit full transgene expression ( Supplementary Fig. 2 ). In both experimental schemes, microglia mounted a typical response to the stimulus. Thus, the absence of reactive microgliosis in the SC during disease in rNLS8 mice does not arise from a globally suppressed microglial phenotype.
Postmortem lumbar SC samples from sALS patients have lessreactive microglia than patients with a SOD1 mutation. Since our finding that microgliosis is not a major feature of the disease course in the SC of rNLS8 mice differs from previous findings in mSOD1 mice, we examined postmortem SC tissues from ALS patients to address the relevance of these disparate results for the human disease. We immunostained lumbar SCs from 5 control patients, 10 patients with clinically probable or definite sALS, 6 ALS patients with a C9orf72 mutation and 4 patients with mutations in SOD1 with IBA-1 to assess reactive microgliosis and NeuN to measure MN loss ( Fig. 2) . We observed dramatically different levels of reactive microgliosis in the gray matter of ALS ventral horns, depending on whether the patient had a SOD1 mutation or not ( Fig. 2e ). There was variability in scores between individual sALS cases, possibly reflecting different, asyet-unidentified etiologies of disease in these patients. However, 50% of sALS cases had microglia levels equal to or less than those of control patients and only 2 sALS patients had microgliosis scores in the same range as samples from patients with mutant SOD1 (Supplementary Table 1 ).
Taken together, patients with a SOD1 mutation had an average inflammation score that was significantly higher than those of sALS patients, patients with a C9orf72 mutation and controls: 2.6 ± 0.5 for SOD1 patients vs. 1.2 ± 1.1 for sALS patients vs. 1.0 ± 0.8 for C9orf72 patients vs. 0.9 ± 0.5 for controls ( Fig. 2e ). Notably, of the 4 patients with identified SOD1 mutations, one did not have clinical symptoms at her time of death (76 years old) nor did she show any postmortem evidence of ALS or any other neurodegenerative abnormalities. We further confirmed that this patient did not have any MN loss specifically in the lumbar SC ( Fig. 2c ). However, the gray matter surrounding those MNs contained an abundance of reactive microglia, suggesting that mutant SOD1-bearing microglia may have important differences in reactivity, independent of neuronal death. We also observed slightly increased IBA-1 reactivity in mSOD1 patients, but not sALS patients, in other brain regions patients with SOD1 mutations, but not consistently in samples from sALS or C9orf72 patients. a-d, Representative images of ventral horn gray matter from 1 of 5 control patients (a), a familial ALS patient with a SOD1 mutation (b), a patient with a SOD1 mutation without clinical or pathological evidence of ALS (c) and 1 of the 10 patients with sporadic ALS (d), immunostained with IBA-1 (white) and NeuN (green), show high levels of reactive microgliosis in samples from patients with indicated mutations in SOD1, but not in sporadic ALS despite obvious MN loss. Scale bar, 100 μ m. e, An average of 3 independent scores per patient shows that patients with the SOD1 mutation, but not sALS patients or those with a C9orf72 expansion, have significantly more reactive microglia in ventral horn gray matter than controls (one way ANOVA, F 3,24 = 3.8, *P = 0.03). Individual data points shown as black circles, with group means ± s.d. shown to the right in red. See Supplementary Table 1 for patient details.
that are not typically associated with ALS ( Supplementary Fig. 3 ). Therefore, the low levels of microgliosis observed in late stage disease rNLS8 mice ( Fig. 1d ) are similar to the SC inflammation in many of the terminal sALS samples from our brain bank.
In early disease recovery, there is a robust increase in reactive microglia. When hTDP43ΔNLS is suppressed after chronic expression, there is a dramatic increase in microglial number and a change in their morphology, concurrent with hTDP-43 clearance from neurons in the rNLS8 SC ( Fig. 3 ). The peak number of microglia in the ventral horn occurs after 1 week of transgene suppression, or 'early recovery' (Fig. 3b ,g), when we detected 157 ± 7.0 IBA-1 + cells per mm 2 in ventral horns of rNLS8 mice. This is significantly more than at 6 weeks off DOX (92.8 ± 5.4 microglia per mm 2 ) and in control rNLS8 SC (82.9 ± 3.0 microglia per mm 2 ; Fig. 3g ). By 8 weeks back on DOX, when hTDP-43 is completely cleared from SC neurons ( Fig. 3c ) and motor symptoms have resolved 27 , microglia return to basal levels, with a ramified phenotype. This process takes place as MN loss is halted ( Fig. 3d -f), with approximately 14 MNs per ventral horn after 6 weeks of DOX removal and reintroduction. Further, during early recovery, the microglia have a reactive morphology, with significantly larger cell bodies ( Fig. 3h ) and shorter, thicker processes ( Fig. 3h ,i). Therefore, in early recovery, the number of SC microglia rapidly increased and morphology changed from ramified to reactive.
To test whether these distinct microglial changes in early recovery relied on prior neuron death, we suppressed hTDP43ΔNLS after only 2 weeks of expression, a time when hTDP-43 is expressed at high levels in the brain and SC 26 but before we detect significant MN death in the lumbar SC 27, 28 (P = 0.7; Fig. 4a -c). Notably, we found a dramatic increase in the number of reactive microglia ( Fig. 4c ) in these rNLS8 mice at the 2 weeks off DOX + 1 week back on timepoint, compared to littermates that were on or off DOX continuously for the whole 3 weeks ( Fig. 4a,b ). We also evaluated motor pools outside of the SC that are resistant to pathological TDP-43 triggered cell death 27 . We found the same pattern of microglial activation after transgene suppression in both the trigeminal nucleus ( Fig. 4d ,e) and facial nucleus ( Fig. 4f ,g), further confirming that this microglial response does not rely on cell death.
We also observed this microglial reaction during recovery in brain regions besides the SC ( Supplementary Fig. 4 ), but this response was not as dramatic relative to disease, probably reflecting intrinsic regional diversity in microglial responses. Further, to explore whether the suppression of hTDP43ΔNLS induces a restricted proliferation of microglia or a global inflammatory response with astrocytosis, we immunostained rNLS8 SCs at various timepoints with GFAP ( Supplementary Fig. 4 ) and found no obvious increase in astrocytosis at any timepoint. We also did not find significant changes in expression of genes associated with the reactive astrocyte phenotype 29 by quantitative PCR in RNA isolated from whole lysates of rNLS8 SC before, during or after disease (Serping1, P = 0.55; Fkbp5, P = 0.22; Emp1, P = 0.42; Supplementary Fig. 4 ).
To investigate whether microglial activation during transgene suppression is a general feature of DOX-inducible mice or is specific . Concurrent with this clearance, there is a dramatic increase in the number of IBA-1 + microglia (red), which peaks at 1 week on DOX and then returns to baseline levels, despite no change in the number of MNs (d-f; VAchT, blue). g-i, After 1 week of transgene suppression, the microglia also have a reactive morphology, with significantly larger cell bodies (h) and shorter, thicker processes (i). Individual data points shown as black circles with group means ± s.d. shown to the right in red. Cntrl, rNLS8 mice maintained on DOX (n = 5); disease, rNLS8 mice that were 6 weeks off DOX (n = 5); recovery, rNLS8 mice that were off DOX for 6 weeks and then on DOX for 1 week (n = 6). Analyses by one way ANOVA: (g) F to tissues in which full-length pathological TDP-43 is being cleared, we examined a different bigenic line of mice with NEFHcontrolled, DOX-inducible expression of a TDP-43 C-terminal fragment (amino acids 208-414, designated '208') 30 during chronic transgene expression and after 1 week recovery ( Fig. 4h-j) . Unlike rNLS8 mice, these NEFH-208 mice do not exhibit MN loss or develop gross motor dysfunction, and the 208 TDP-43 C-terminal fragments do not induce nuclear TDP-43 clearance or form large cytoplasmic inclusions ( Supplementary Fig. 5 ). We found no difference in microglia counts in the lumbar SC of NEFH-208 mice that were continuously off DOX versus 1 week recovery (88 ± 3.7
vs. 90.6 ± 3.3 microglia per mm 2 ; Fig. 4j ), which is in contrast to the ~70% increase that we see with suppression of the mutant fulllength TDP-43 in the rNLS8 line.
Increased microgliosis results from central proliferation and not infiltration of peripheral myeloid cells.
To determine whether the source of the increased microgliosis during early recovery in rNLS8 mice is entirely due to local proliferation or is accompanied by peripheral infiltration, we performed two separate experiments: one that involved labeling peripheral circulating myeloid cells and the other based on depleting them and assessing whether the microglial 
Fig. 4 | After transgene suppression, microglial activation is independent of prior neuron death. a-c,
Representative images of rNLS8 lumbar SC stained with hTDP-43 (green) and IBA-1 (red) shows immunoreactive hTDP43Δ NLS in MNs at the 3 weeks off DOX timepoint (b), but no change in microglia numbers or morphology. However, when the transgene is suppressed for 1 week, after hTDP-43 expression but before MN death (c), there is a dramatic increase in reactive microglia. Similar staining was seen in n = 6 mice per DOX treatment group. d-g, The same pattern of microglial activation is seen in brainstem nuclei labeled with VAChT (green) and IBA-1 (red), despite no prior cell death of trigeminal (e) or facial (g) MNs. Similar brainstem nuclei staining was seen in 4 rNLS8 mice per DOX treatment. h-j, Mice with the same inducible system under the same NEFH promoter that express C-terminal fragments of hTDP-43 (amino acids 208-414) do not have the same pattern of microglial activation after neuronal expression (h) and 1 week of clearance of hTDP-43 C-terminal fragments (i; designated NEH8-208 Recovery in the dot plot) with mean microglia density for each group indicated by the red line (j; NEFH-208, n = 3 per group; rNLS8, n = 5 per group; unpaired, two-tailed t test, t = − 17.6, ***P = 0.0000002). Scale bars, 100 μ m.
response was attenuated. First, whole body irradiated rNLS8 mice were rescued with bone marrow cells from actin-GFP mice so that their peripheral immune system was reconstituted by GFP-tagged donor-derived cells. Two months later, chimeric mice were separated into three groups: (i) control: rNLS8 mice maintained on DOX; (ii) disease: rNLS8 mice off DOX for 4 weeks; and (iii) recovery: rNLS8 mice off DOX for 6 weeks followed by 1 week on DOX ( Fig. 5a ). We confirmed that the peripheral immune system was successfully , had DOX removed for 4 weeks (n = 6) or were off DOX for 6 weeks + on DOX for 1 week (n = 6). b, Representative cryosection of an irradiated rNLS8 mouse spleen stained with IBA-1 (red) shows GFP + macrophages, indicating the successful engraftment observed in all 16 mice. c, At 6 weeks off DOX + 1 week on, there was increased reactive microglia in the lumbar SC (IBA-1, red), but these cells were GFP -(green), a consistent result in all animals d, Experimental timeline: rNLS8 mice were 6 weeks off DOX + 1 week on, and given injections (i.p.) of either clodronate-or PBS-liposomes 10 d before analysis. e,f, Representative cryosections of spleen from rNLS8 mice that were injected with PBS-liposomes (e) or clodronate-liposomes (f) immunostained with F4/80 (green), IBA-1 (red) and DAPI (blue) show intact splenic macrophages after PBS-liposome administration, but ablated populations after clodronate-liposome treatment. g-k, Depleting peripheral myeloid cells had no effect on microgliosis. Individual data points shown as black circles, with group means ± s.d. shown to the right in red (n = 4). l, Representative cryosection of lumbar SC from 1 of 3 rNLS8 mice during peak microgliosis shows that the microglia are negative for CD44, a marker of peripheral myeloid cells. Scale bars, 100 μ m.
reconstituted with GFP + cells by immunostaining the spleen ( Fig. 5b ) and liver and using flow cytometry to identify CD11B + GFP + cells in blood. The microglial response pattern was unchanged in chimeric rNLS8 mice, with little microglia activation during disease and a sharp increase during recovery. In all groups, the microglia were GFP -, suggesting that the increased number of IBA-1 + cells during early recovery did not include infiltrated cells (Fig. 5c ). Clodronate-filled liposomes trigger apoptosis in myeloid cells 31 , and so were used to dramatically reduce peripheral macrophage populations, but not resident microglia, in rNLS8 mice during early recovery ( Fig. 5d-f and Supplementary Fig. 6 ). This depletion had no effect on microgliosis during early recovery in rNLS8 mice ( Fig. 5g-k) , in which both phosphate-buffered saline (PBS)and clodronate-liposome-treated animals had the same marked increase in reactive microglia in the SC (139 ± 16 vs. 137 ± 22 IBA-1 + cells per mm 2 , for the clodronate-and PBS-treated mice, respectively). Further, CD44 has recently been identified as a marker for infiltrating immune populations 32 , and we found that the microglia in the rNLS8 SC during recovery were CD44 negative ( Fig. 5l ). Finally, to document rapid proliferation of resident microglia following hTDP43ΔNLS suppression, 6 weeks off DOX or early recovery rNLS8 mice were injected daily for 1 week with 5-bromodeoxycytidine (BrdU, 50 mg/kg, i.p.). Early-recovery rNLS8 mice had ~12 BrdU + IBA-1 + cells per ventral horn, compared to only ~2 BrdU + microglia per ventral horn in rNLS8 mice at 7 weeks off DOX ( Supplementary Fig. 7 ). Taken together, these three experiments indicate that microgliosis after transgene suppression arises from the proliferative response of resident microglia, not invasion from the periphery.
Transcriptomic profiling of microglia isolated from rNLS8 mice reveals unique disease-and recovery-associated changes. Total RNA was extracted from CD11b + CD45 lo microglia from SCs of rNLS8 mice during early and intermediate disease timepoints (2 and 6 weeks off DOX, n = 7 and 8), early recovery (6 weeks off + 1 week back on DOX, n = 9) and control mice (rNLS8 mice maintained on DOX and DOX-matched nTg mice, n = 14 total) for sequencing to determine disease-and recovery-relevant gene-expression changes in these cells ( Supplementary Fig. 8 ). The microglia cell lineage was confirmed by gene expression of microglial genes (for example, Cx3cr1 and Irf8), but few or absent markers for astrocytes (Gfap) and neurons (Nefh; Supplementary Fig. 8 ). Principal component analysis and unsupervised hierarchical clustering revealed some overlap between different disease samples, with the early disease and control samples being particularly intermingled, and variability in the late disease replicates ( Supplementary Fig. 8 ). However, late disease and recovery signals could be clearly distinguished when directly compared (Fig. 6a) .
Despite observing only a 10% increase in the number of SC microglia and no obvious change in their morphology at 6 weeks off DOX ( Fig. 1) , we found 465 genes that were changed over 1.5-fold at that timepoint relative to control ( Fig. 6b and Supplementary Fig. 9 ). Of the genes that were upregulated, many were part of pathways associated with the production of inflammatory molecules (for example, Hmgb1 and Trem1 signaling pathways; Supplementary Fig. 9 ).
Previous microglia profiling studies in mSOD1 and other mouse models of neurodegeneration have identified transcriptional signatures associated with long-term disease [33] [34] [35] , and we next wanted to compare these with the gene-expression changes in rNLS8 microglia. First, Chiu and colleagues hypothesized that mSOD1 microglia express both neurotoxic and neuroprotective factors 33 . We thought these phenotypes might be more differentiated in our samples during late disease and early recovery, but instead found that many of the identified putative 'neurotoxic' genes were similarly upregulated in both sets of samples (for example, Mmp12 and Cybb; Supplementary Fig. 10 ). Further, Krasemann and colleagues identified homeostatic genes that were downregulated in neurodegeneration, such as Tgfb1, Jun and Mef2a, but none of these were consistently changed across our samples ( Supplementary Fig. 10) . However, the genes that they found to be upregulated (for example, Apoe, Itgax, Spp1) were also upregulated in rNLS8 microglia taken from both late disease and early recovery 34 . Finally, Keren-Shaul et al. identified genes that were upregulated in microglia during neurodegenerative disease progression (such as Lpl, Ctsb and Ctsd), which they called DAM 35 . Again, these genes were upregulated similarly in both late disease and recovery in rNLS8 microglia ( Supplementary  Fig. 10 ). These findings suggest that those gene sets are in fact associated with disease, but not exclusively. When hTDP43ΔNLS was suppressed for 1 week, 171 of the genes that are up in late disease were downregulated (Fig. 6c) . Many of these genes were related to changes in RNA processing, including those involved in mRNA splicing (Clasrp, Pabpn1, Ccnl2), RNA binding (Cirbp) and protein transcription (Gabpb2), and we identified 'alternative splicing' as a suppressed gene ontology pathway. This result is noteworthy, given the importance of normally functioning nuclear TDP-43 for proper RNA processing 36 and given the downregulation of endogenous mouse TDP-43 after chronic expression of hTDP43ΔNLS 26 .
Further, compared to control samples, 125 genes were upregulated over 1.5-fold in recovery ( Fig. 6d,e ), and 76 of these genes were uniquely upregulated when compared to changed genes during late disease ( Fig. 6d and Supplementary Fig. 10 ). These genes comprise several pathways, including cell adhesion molecules and phagosome (Database for Annotation, Visualization and Integrated Discovery, v.6.8; https://david.ncifcrf.gov/) and antigen presentation (Ingenuity Pathway Analysis). These gene changes fit well with observations that microglia often directly contact neurons following transgene suppression, with some surviving neurons being nearly completely surrounded by reactive microglia (Fig. 6f ). This apparent contact and the upregulated genes associated with phagosome formation next led us to consider whether these microglial functions might account for hTDP-43 clearance after transgene suppression ( Fig. 7) .
Microglia clear neuronal hTDP-43, and this is selective over other cytosolic neuronal proteins.
Given the gene expression signatures and the increase in microglial expression of CD68 (Fig. 5i,j and Supplementary Fig. 11 ), we next asked whether microglia might be active participants in the clearance of hTDP-43 from neuronal cytoplasm. Following transgene suppression, we found that microglia that were not surrounding neurons contained hTDP-43 and expressed CD68 ( Fig. 7a and Supplementary Fig. 11 ). In contrast, microglia at 6 weeks off DOX rarely contained hTDP-43 ( Fig. 7b) , with an average of 28.5 IBA-1 + cells containing hTDP-43 at 1 week recovery, compared to ~4 at 6 weeks off DOX (48.7 ± 2.2% of all ventral horn microglia vs. 10.2 ± 3.3%). If nonviable neurons were nonspecifically releasing their contents or if microglia were engulfing dead cells, we reasoned that other cytoplasmic neuronal proteins would also be detected in the microglia during early recovery, but we found that other neuron-specific proteins were rarely within microglia ( Supplementary Fig. 12 ). This suggests that hTDP-43 is being selectively cleared by microglia, though we cannot rule out the possibility that the other neuronal proteins may just be under the detection limit of immunofluorescence. The means by which hTDP-43 is taken up by microglia during recovery remains uncertain, but selective release of hTDP-43 from neurons could precede its uptake by microglia.
We next overexpressed another protein in rNLS8 SC MNs to exclude the trivial possibility that the differential proportion of hTDP-43-bearing microglia resulted from hTDP-43 being overexpressed. Newborn rNLS8 mice were injected with AAV9.GFP (intracerebroventricularly or i.c.v.) to tag MNs with GFP ( Supplementary  Fig. 13 ). When these mice reached adulthood, we removed DOX for 6 weeks, followed by 3 d or 1 week back on DOX ( Fig. 7c-h) . GFP levels remained high in SC MNs, but were absent from microglia during recovery in AAV.GFP-injected rNLS8 mice (Fig. 7e,f ). In contrast, the majority of these microglia contained hTDP-43, suggesting that the uptake of neuronal hTDP-43 is very selective over other cytosolic proteins, even when they are overexpressed (Fig. 7g,h) .
Microglia are necessary for motor recovery after hTDP43ΔNLS suppression in rNLS8 mice. To elucidate the functional role that microgliosis plays during the recovery phase in rNLS8 mice, we used a dual CSF1R and c-kit inhibitor, PLX3397 37 , to assess the consequence of microglia suppression on motor recovery. rNLS8 mice were taken off DOX for 4 weeks and then subsequently given DOX for 2 weeks. For the last 3 weeks of this timeline, rNLS8 mice received chocolate-hazelnut spread (Nutella) in a petri dish at the bottom of their cage daily, either by itself (n = 5) or with PLX3397 mixed in at 1,000 mg/kg (n = 5; Fig. 8a ). The motor symptoms in rNLS8 mice given Nutella only were largely resolved after 2 weeks of transgene suppression (Fig. 8c ). However, all of the rNLS8 mice that were treated with PLX3397 still displayed hindlimb clasping and some maintained a hunched posture (Fig. 8b,c) . Further, compound muscle action potentials recorded from gastrocnemius trended lower in PLX3397-treated mice compared to controls (Fig. 8d ). PLX3397 significantly blocked the increased microgliosis at 2 weeks recovery in all tested rNLS8 mice, even depleting microglia levels below that of nTg mice in 3 of the 5 mice (Fig. 8e ). We speculate that the variability in the amount of microglia reduction stemmed from differences in Nutella consumption, despite all mice having equal access. There were no apparent differences between the two groups in the number of SC astrocytes.
We next analyzed the consequence of microglia depletion on clearance of hTDP-43. hTDP-43 was still strongly detected by immunofluorescence in the PLX3397-treated rNLS8 mice, but not in controls ( Fig. 8f-h) . Ventral horn hTDP-43 levels varied inversely with microglia density, suggesting that microglia are needed for clearing the intracellular pathological TDP-43 (Supplementary Table 2 ), and consistent with the possibility that the mechanism of clearance requires microglial-neuronal contact. Notably, we confirmed by quantitative PCR that hTDP43ΔNLS was suppressed in all rNLS8 mice after 2 weeks of DOX reintroduction, regardless of treatment group ( Supplementary Fig. 14) .
We also found that control rNLS8 mice had 14% more intact neuromuscular junctions in the tibialis anterior than PLX3397 treated mice, suggesting that axonal dieback continued in the microglia-depleted animals despite transgene suppression (Fig. 8i ). rNLS8 SCs also had significantly fewer MNs after microglial reduction ( Fig. 8j-l) . However, the remaining microglia in PLX3397treated SCs still appeared to be functional, as they expressed CD68 (Fig. 8m,n) , LPL and Trem2 ( Supplementary Fig. 14) . Moreover, the amounts of microglial depletion varied tightly with the effect on recovery parameters. Animals with the fewest microglia following PLX3397 treatment had the lowest compound muscle action potentials, the fewest remaining lumbar MNs, the most tibialis anterior denervation and the least clearance of hTDP-43 from SC neurons ( Supplementary Table 2 ). This was not an effect of the drug itself, as the same administration regime did not affect the neuromuscular system of nTg controls ( Supplementary Fig. 14) . Therefore, reducing microglia by 35-90% in rNLS8 mice dramatically altered recovery after transgene suppression.
Discussion
Our results show that microglia are critically involved in recovery from a sALS-like neurodegenerative disease in the SC that is linked to mislocalization and aggregation of TDP-43 in the rNLS8 mouse model. When TDP-43 triggered MN disease processes are halted, there is a dramatic increase in reactive microglia, concurrent with hTDP-43 clearance and functional motor recovery. When this increased microgliosis is blocked, rNLS8 mice fail to make a full recovery over the course of 2 weeks. The full spectrum of microglial activities associated with recovery remains to be determined, although the active, contact-dependent clearance of pathological TDP-43 from neurons is likely to play a central role.
In mouse models involving peripheral nerve transection, microglia have been shown to become activated, surround injured MNs and displace synapses in a process dubbed 'synaptic stripping' , all of which precedes regeneration 38, 39 . Given that we saw a similar pattern of microgliosis in rNLS8 mice after transgene suppression, before the MNs expanded their innervation field and began to express proteins that they typically do not express 27 , it is intriguing to speculate that microglia may contribute to this plasticity. Furthermore, compelling studies over the last 5 years show that microglia can be active participants in circuit refinement and pruning processes 40 . Debris clearance by microglia declines with aging and is associated with an inadequate regenerative response 41 . We previously showed that aged rNLS8 mice had a diminished recovery relative to young mice 28 , and we now propose that microglial senescence may be a contributing factor.
Further, we also showed that microgliosis arises as a result of a proliferative response from resident CNS microglia (Fig. 5 ). But what cues launch this proliferation and why aren't these signal(s) deployed during the disease process? We know that it is not simply an effect of DOX on mice, because neither NEFH8-208 nor nTg mice showed changes in microgliosis in response to DOX being removed or added to their diet (Fig. 4j) . Moreover, the signal for proliferation cannot simply lie downstream of the accumulation of pathological TDP-43, because these accumulations are very abundant throughout the disease course in the SC and yet microglia levels remain stable. Another question of interest is, would pathological hTDP-43 be transmitted to other neurons and seed further TDP-43 aggregation if the microglia were not available to eliminate it? Perhaps of greatest translational relevance, if we could selectively induce the relevant microglia functions during disease, would the progression of ALS be arrested? Finally, it has been demonstrated that microglia in different brain regions have intrinsic baseline differences in gene expression and sensitivity [42] [43] [44] , so fully exploring microglial responses to disease and recovery in other brain regions will be an interesting future direction.
Our results are markedly different from previous findings in studies of other mouse models of ALS. For example, studies in the mSOD1 mouse model showed that eliminating microglia is beneficial 18 . We think the critical difference between these mice and our rNLS8 mice is that the rNLS8 mice have wild-type microglia and an intact blood-brain barrier ( Supplementary Fig. 6 ). Nevertheless, those studies in mSOD1 mice generated great excitement in the use of anti-inflammatory drugs to treat ALS patients, but no such drugs have successfully been translated to therapeutic success in ALS patients. In this study, when we looked at postmortem SC tissue in the areas immediately surrounding MNs in 25 individuals, we found that most sALS patients only showed occasional increases in microgliosis relative to controls, but all patients harboring SOD1 mutations showed extensive microgliosis (Fig. 2 ). This suggests that rNLS8 mice may be a more translatable model for the vast majority of sALS patients, with respect to microglial inflammation.
Altogether, our study shows that microglia in the environment of MNs can have a positive impact on their survival and ultimately in their recovery from disease. We found that genes associated with cellular contact and phagosome formation are uniquely upregulated in microglia during recovery, which may mediate their protective interactions with surviving MNs. Though there are currently no clinical strategies available to effectively target TDP-43 in patients, this research suggests that doing so in combination with encouraging appropriate microgliosis could be a valuable therapeutic direction. Further, using this inducible transgene system to activate microgliosis allows us to model microglia proliferation for repair separately from proliferation in response to nerve injury itself.
Finally, researchers have previously called for the targeting and reduction of microglial cells in order to slow ALS disease progression 45 . We now propose the opposite strategy; that is, findings ways to encourage appropriate microglia-mediated inflammation during the onset and progression of ALS to clear pathological TDP-43 proteins and boost axonal regeneration. Understanding the impact of normally functioning microglia on TDP-43 clearance and axonal outgrowth may provide new therapeutic strategies for patients even in late disease stages.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0083-7.
Tg and nTg mice. As described previously 26 , rNLS8 mice were generated by crossing new Tg lines overexpressing the tetracycline transactivator (tTA) protein under the control of the human NEFH promoter with an existing Tg line that can be induced with DOX manipulation to express human TDP-43 with a defective nuclear localization signal (hTDP-43Δ NLS). Bigenic 208 TDP-43 Tg mice were produced by crossing tetO-208 TDP-43 Tg mice with the NEFH-tTA Tg mice. For both lines, a DOX diet (Dox Diet #3888, Bio-Serv) inhibits tTA from binding to the tetracycline promoter element, repressing hTDP-43 expression. When mice are taken off DOX and given standard chow (Rodent Diet 20 #5053, PicoLab), hTDP-43 expression is activated. For all studies, male and female mice were used, and mice were between 2 and 5 months old when DOX was initially removed from their diets. Randomization was not possible for group selection when comparing rNLS8 mice to controls, because the animals needed to be genotyped. However, after genotyping, rNLS8 mice were randomly assigned to different DOX treatment conditions and/or drug treatment. Experimenters were blinded to the genotype/ treatment of each mouse during data collection and identities were decoded later for analysis, using identification numbering based on toe tattooing. Sample sizes were chosen based on prior publications using these mice [26] [27] [28] . All procedures were performed in accordance with the NIH Guide for the Care and Use of Experimental Animals. Studies were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Nerve crush. The lateral thigh of rNLS8 or nTg mice (n = 4 each, 2 weeks off DOX) was shaved, and a 0.5-to 1-cm incision in the skin was made over the lateral femur. The sciatic nerve was localized and crushed with a hemostat for 15 s. The skin incision was closed with silk sutures and the animals were allowed to recover on a warming blanket.
LPS injections. rNLS8 mice that were 2 weeks off DOX (n = 6) or nTg (n = 3) were injected with LPS at 4 mg/kg (i.p.) at a volume of 10 mL/kg; they were killed by perfusion 6 or 18 h later and their SCs were prepared for immunostaining, as described below.
Irradiation experiments. Adult rNLS8 mice received whole-body lethal irradiation using 950-rad (9.5-Gy) gamma irradiation delivered for 10 min. One to 2 h after irradiation, mice received a bone marrow transplantation of approximately 5 × 10 6 cells administered in a total volume of 200 µ L via tail vein injection using a 30-gauge needle. Animals were allowed to fully recover from the procedure for 8 weeks. After recovery, in two of the three groups of animals ( Fig. 5a ), DOX treatment was stopped in order to initiate disease processes, including those that were allowed to progress in the disease state for 4 weeks before being killed for analysis and those that were placed back on DOX chow after 6 weeks of disease in order to allow for a recovery phase.
BrdU treatment. rNLS8 mice that were 6 weeks off DOX were either reintroduced to DOX (n = 4) or kept on the standard diet (n = 4). These animals were injected daily with BrdU (Sigma-Aldrich) at 50 mg/kg (i.p.) for 6 d and were killed by perfusion 24 h after the last injection to assess the presence of newborn cells in the spleen and lumbar SC in early recovery or during disease.
Injection of liposomes.
Clodronate-and PBS-loaded liposomes were purchased from Lipsoma. The suspension of liposome encapsulated clodronate is approximately 5 mg of clodronate per 1 mL of the suspension. nTg (n = 6) or rNLS8 mice off DOX (n = 7) were injected with clodronate liposomes or PBS liposomes (10 mL/kg, i.p.) 3 d before DOX was reintroduced to the animals' chow and continued for an additional 7 d while the animals recovered on DOX. This protocol was based on discussions through the web site http://www.clodronateliposomes.org/. PLX3397 treatment. PLX3397 (1Click Chemistry) mixed into Nutella at 1,000 mg/kg, or Nutella only, was added to polysterene culture dishes, placed at the bottom of cages housing nTg or rNLS8 mice, and changed every 24 h for 3 weeks. We found Nutella to be a suitable vehicle for voluntary oral ingestion, and chose it as a less stressful alternative to gavage. Each animal ate 0.5-1.25 g Nutella over the course of the 24 h, in addition to 2-3 g of regular or DOX chow (Fig. 8a) .
Experiments with viral vectors. AAV9.CMV.PI.eGFP.WPRE.bGH (3.3 × 10 13 GC/mL, Penn Vector Core) was thawed on ice and the virus solution was colored by addition of a small amount of Fast Green dye (Sigma-Aldrich, St. Louis, MI). For i.c.v. injections, P1 pups were anesthetized by hypothermia and, using a 31-gauge 0.5-cc insulin syringe (BD Ultra-Fine* II Short Needle Insulin Syringe, VWR), 2 μ L of virus was injected into the third ventricle. Successful injection was confirmed by bilateral spread. If the dye did not spread to both ventricles, the injections were deemed unsuccessful and the pups were killed. Remaining pups were returned to their mother and health was monitored to adulthood.
Muscle physiology. To perform the CMAP recordings, mice were anesthetized and their hind legs were shaved. The sciatic nerve was stimulated through bipolar needle electrodes by injecting brief electrical currents (0.3 Hz, 0.5-ms pulse duration, starting at 0 mA and incrementally increasing by 5 mA). The response from the gastrocnemius was recorded using needle electrodes placed in the center of the muscle and in the tendon. The M-wave was measured at each amplitude, until the maximal response was elicited and did not increase further. Maximum evoked amplitudes were analyzed using pClamp 10 software (Molecular Devices).
Preparation of mouse lysates and qPCR.
Mice were perfused with phosphate buffered saline (PBS), and a fast dissection was performed to remove cortex and SC. Mouse tissue samples were homogenized in QIAzol lysis buffer (Qiagen), chloroform was added, and samples were spun down at 12,000 rpm at 4 °C for 15 min. RNA was isolated using miRNeasy Kit (Qiagen). Quality and concentration were tested using NanoDrop 2000. RNA was then reverse transcribed to cDNA using SuperScript III (Invitrogen). Quantitative polymerase chain reaction (qPCR) was performed on the cDNA using SYBR Green PCR Master Mix (Life Technologies) and the following primers: for hTDP43, CCTAATTCTAAGCAAAGCCAAGATG and ACAGCGCCCCACAAACA; for Emp1, GAGACACTGGCCAGAAAAGC and TAAAAGGCAAGGGAATGCAC; for Serping1, ACAGCCCCCTCTGAATTCTT and GGATGCTCTCCAAGTTGCTC; and for Fkbp5, GGCAAACTCTAGGAGGCTTAAA and CTTACAGCTCCCACCAGAATAC. The qPCR plate was read using Applied Biosystems 7500 Fast Real Time PCR system. Gene expression was measured relative to Actb (β -actin). Three technical replicates were run for each sample.
Immunofluorescence and quantification. rNLS8 mice, 208 TDP-43 Tg mice and nTg controls were perfused with ice-cold PBS followed by 10% formalin, and then the brain, lumbar SC, spleen, liver and hindlimb muscles were surgically removed. Peripheral tissues were washed in PBS overnight, and the CNS tissue was postfixed in 10% formalin overnight. All were then washed in PBS and then processed in a sucrose gradient up to 30% for cryoprotective embedding.
To analyze MN populations in the brainstem and lumbar SC, tissues were sectioned at 20 µ m and immunostained using the following primary antibodies: guinea pig anti-VAChT (1:1,000, CNDR), rabbit anti-VAChT (1:5,000, CNDR), mouse anti-hTDP-43 monoclonal antibody (MAb; 0.06 μ g/mL, CNDR, clone 5104), rat anti-CD68 (1:200, Bio-rad, MCA1957), rat anti-Cd11b (1:200, Bio-rad, MCA711), rabbit or goat anti-IBA-1 (1:1,000, Wako, 019-19741, and Novus, NB100-1028), goat anti-CHAT (1:500, Millipore, AB144P), mouse anti-NeuN (1:5,000, Millipore, ABN78), sheep anti-Trem2 (1:500, R&D Systems, AF1729), rabbit anti-CD44 (1:100, Millipore, MABF580), mouse anti-LPL (1:50, Abcam, Ab21356), rabbit anti-GFAP (1:5,000, Dako, Z0334) and rat anti-BrdU (1:1,000, Bio-rad, MCA2060GA).
After overnight incubation with primaries, sections were washed and then incubated with Alexa Fluor 488, 568 or 647 secondary antibodies (1:1,000, Molecular Probes). Tissues were imaged using either a Nikon Eclipse Ni inverted microscope or a Leica TCS SPE. For the confocal imaging of microglia, 10 z-steps spaced 1-3 µ m apart were collected per image, and a maximum projection was created for each.
To quantifiy MN numbers, MNs were counted in transverse 20-μ m cryosections, 100 μ m apart, over the length of 1 mm. For quantification and morphological analysis of microglia, IBA-1 + DAPI + copositive cells were counted in the ventral horn gray matter only over the length of L3-L5, using Image J and NIS-Elements software.
For spleen and liver, sections were cut longitudinally at 10 µ m and immunostained with rat anti-F4/80 (1:200, Bio-rad, MCA497GA) and IBA-1.
The TA muscle was sectioned at 30 µ m longitudinally, and immunostained with VAChT to label nerve terminals and α -bungarotoxin conjugated to Alexa Fluor-488 (BTX, 1:1,000) to label motor endplates. The percentage of NMJs innervated was determined by dividing the total number of areas of overlap between VAChT and BTX signals (total number of innervated endplates) by the number of areas of BTX signal (total number of endplates) on consecutive longitudinal 30-μ m cryosections of muscles. We observed 400-1,000 NMJs per TA.
Microglial isolation. Mice were euthanized with a ketamine/xylazine cocktail and perfused with ice-cold PBS. SCs were flushed from the spinal column using PBS and placed in ice-cold HBSS with HEPES. Tissue was homogenized using Wheaton (Millville, NJ, USA) tissue grinders to achieve a single cell suspension. The homogenate was centrifuged through a 30% Percoll (GE Healthcare) gradient to remove myelin and enrich for microglia. After washing with FACS buffer (HBSS, HEPES, BSA, EDTA) cells were Fc-blocked (CD16/32, Cat. #101321, Biolegend, San Diego, CA, USA) and stained with CD11b-PE (Cat. #553311, BD Biosciences, MA, USA) and CD45-BV421 (Cat #103134, Biolegend). DRAQ7 was used for dead cell exclusion. Cells were sorted on an ARIA Fusion Flow Cytometer and collected directly into RNA lysis buffer (Buffer RLT, Qiagen, Hilden, Germany). A portion of cells were sorted into the FACS buffer to assess purity. DRAQ5 was used to mark all nucleated cells post sort. Purity was greater than 90%.
RNA processing. RNA was isolated with the RNeasy Micro Kit Plus (Qiagen). RNA quality was assessed on the 2100 Bioanalyzer with the RNA 6000 Nano Kit (Agilent, Santa Clara, CA, USA) and quantified using Quant-iT RiboGreen (Life Technologies, Carlsbad, CA, USA). Libraries were constructed using the SMART-Seq Ultra Low-input (Clontech, Mountain View, CA, USA) and NexteraXT kits (Illumina, San Diego, CA, USA). Libraries were sequenced at an average depth of 20 million paired-end reads.
Transcriptomic data analysis. After sequencing, FASTQ files were generated by clustering BCL files to paired FASTQ files with a BCL2FASTQ pipeline, in line with standard Illumina sequence generation. RNA-seq analysis was performed in the commercial platform Omicsoft Arraystudio, including raw RNA-seq data quality control, filtering and trimming of reads, and alignment to the mouse genome (mm10 assembly, with gene annotations from Gencode release M6 and Ensembl81) using the Omicsoft OSA4 aligner 46 . More than 30 million paired-end fragments were generated from each RNA sample analyzed, with the percentages of uniquely and nonuniquely mapped paired-end reads ranging from 89 to 92% and 3 to 5%, respectively, which was consistent with high-quality RNA-seq data. Genelevel quantification of aligned reads was performed in Omicsoft using a module adopted from RSEM 47 , and differential gene expression was performed using an Omicsoft implementation of DESeq2 48 . Plots were generated in the OmicSoft interface and using BioVenn 49 . Pathway insights were obtained using the Ingenuity Pathway Analysis (IPA) software from Qiagen.
Human study. Detailed clinical characteristics (disease duration, age at death, site of onset, etc.) were ascertained from an integrated autopsy database at CNDR. Genotyping for a C9orf72 repeat expansion or the coding regions of other genes associated with ALS/FTLD-TDP (SOD1, TARDBP, UBQLN2) were performed as previously reported 50 . Sample sizes were based on availability of patient material, which was donated and autopsied at the Center for Neurodegenerative Disease Research (University of Pennsylvania) between 2008 and 2016. Patient details can be found in Supplementary Table 1 . Written informed consent for autopsy and analysis of tissue sample data was obtained for all patients, either from the patients themselves or their next of kin. Samples were obtained with ethics committee approval.
For microglial pathology analysis, lumbar section of 6 or 20 µ m thickness were cut from paraffin-embedded specimens. For IHC, all slides were deparaffinized and rehydrated in a series of xylene and graded ethanol. Microwave antigen retrieval was performed with Vector Antigen Unmasking Solution at a 1:100 dilution in dH 2 O for 15 min at 95 °C. After cooling, slides were washed in 0.1 M Tris buffer (pH 7.6) and blocked in 0.1 M Tris/2% FBS. Sections were stained using polyclonal rabbit anti-Iba1 antibody (1:1,000, Wako Chemicals) and mouse anti-NeuN (1:1,000, Millipore) and incubated overnight at 4 °C. Sections were then rinsed and washed in Tris, blocked in 0.1 M Tris/2% FBS, and then incubated with Alexa Fluor secondary antibodies (1:1,000, Molecular Probes) for 2 h. After incubation with secondary antibodies, sections were washed and briefly immersed in 0.3% Sudan Black in 70% ethanol to reduce background autofluorescence. The extent of microglial activation of the ventral horn gray matter was rated on a fourpoint ordinal scale (0, none; 1, mild; 2, moderate; 3, severe/numerous) by three independent investigators and these scores were averaged.
Statistics and reproducibility.
All experiments described in this paper were performed once, using 3-8 independent animals per group as defined in figure legends. At least 10 sections of SC were imaged per animal (sampled over the length of 1 mm), yielding at least twenty 10× images per animal. No data points were excluded from analysis in any experiment, although the TA of one animal was not analyzed in the PLX3397 treatment study due to experimenter error during tissue sectioning. Data were checked for normality using the Shapiro-Wilk method and equal variance by the Brown-Forsythe method. Statistical significance was determined using unpaired or paired two-tailed t tests when comparing two groups and one-way ANOVA when comparing multiple groups, using SigmaPlot. For significant results by one-way ANOVA, all pairwise multiple comparisons were made using the Holm-Sidak method. A P value of less than 0.05 was considered significant.
Accession code. GEO: RNA-seq data, GSE109171.
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Data availability and accession code.
Additional data supporting the findings of this study are available from the corresponding author upon request. The GEO accession code for the RNA-seq data is GSE109171.
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Experimental design 1. Sample size
Describe how sample size was determined.
In order to decide the sample size required to detect a difference in the recovery of motor function (CMAP) and other neuromuscular integrity measures (TA innervation, motor neuron counts in the lumbar spinal cord), we performed a power analysis based on the results reported in Spiller et al, Acta neuropathologica communications, 2016. We calculated that we needed at least an n=4 to detect a 20% difference, 80% of the time. We had n=5 in the PLX3397-treated group and n=5 in the sham control.
For the quantification of human data reported in Figure 3 , we were limited to n=4 for the patients with a SOD1 mutation, because these are all of the cases that were donated and autopsied between 2008 and 2016 here at the Center for Neurodegenerative Disease Research. With that limitation, the power of the ANOVA that was performed with alpha=0.05: 0.628. We found a significant different in the number of activated microglia in SOD1 patients relative to control patients (n=5) and to sporadic ALS patients (n=10), but no difference between control and sporadic ALS patients (F=5.0, p=0.02, post-hoc comparisons by Holm-Sidak method).
Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
For IF and qPCR, all experiments include independent samples for replication. Samples were derived from between 3 and 8 independent animals per group (exact numbers indicated in figure legends). For qPCR, 3 technical replicates were run per animal and the Ct values of these replicates were averaged. For quantification of IF images, at least 20 images were analyzed per animal. All qualitative staining analyses were stained and assessed/scored by at least 2 different experimenters (authors C.R.R., M.A.D., and T.K.). "Symptom scores" for the animals in the PLX3397 were given by at least 2 experimenters, and videos were taken of each animal in case of disagreement.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For irradiation, BRDU, liposome, and PLX3397 treatment experiments, all rNLS8 animals were allocated randomly, but groups were counterbalanced for animal sex and group average body weight.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For microglia counts, slides were stained and imaged and the pictures were saved with only a number to identify them (and no treatment indication) by C.R.R. Images were then quantified by K.J.S., M.A.D, and/or T.K. and, after all were counted, these were unblinded and group statistics were performed.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
We used SigmaPlot 13 for all statistical analyses. Images were collected and processed using LAS X (for Leica confocal), Image J, and NIS-Elements software. Evoked compound muscle action potentials were recorded and analyzed using pClamp 10 software. FlowJo v10 was used for microglia sorting experiment. For bioinformatic analyses, we used the BCL2FASTQ pipeline, STAR, Expectation Maximization (RSEM), OmicSoft, and Ingenuity Pathway Analysis (IPA).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials are commercially available, with the exception of the CNDR antibodies (hTDP-43, VAchT), which we can provide if requested.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
